Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Background: Although approximately half of adult patients with acute lymphoblastic leukemia (ALL) achieve long-term survival, those who relapse have poor long-term outcomes (El Fakih et al. Hematol Oncol Stem Cell Ther. 2017; Oriol et al. Haematologica. 2010). The initial report of Phase 1 of ZUMA-3...
Saved in:
Published in | Blood Vol. 132; no. Supplement 1; p. 897 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
29.11.2018
|
Online Access | Get full text |
Cover
Loading…
Abstract | Background: Although approximately half of adult patients with acute lymphoblastic leukemia (ALL) achieve long-term survival, those who relapse have poor long-term outcomes (El Fakih et al. Hematol Oncol Stem Cell Ther. 2017; Oriol et al. Haematologica. 2010). The initial report of Phase 1 of ZUMA-3, the Phase 1/2 trial of KTE-C19 for treatment of relapsed/refractory (R/R) ALL (NCT02614066), has thus far demonstrated promising efficacy among patients infused with KTE-C19, with a 71% complete remission (CR) rate (CR or CR with incomplete hematologic recovery [CRi]), 88% undetectable minimal residual disease (MRD), and manageable toxicity across all doses (Shah et al. ASH 2017. #888). Here, we present updated safety and efficacy data from Phase 1 of ZUMA-3.
Methods: Adult patients (≥ 18 y) with R/R ALL (Ph+ allowed), > 5% bone marrow blasts, and ECOG 0-1 received 2, 1, or 0.5 × 106 CAR T cells/kg after low-dose conditioning chemotherapy with fludarabine 25 mg/m2/day for 3 days and a single dose of cyclophosphamide 900 mg/m2 on the third day of conditioning. The primary endpoint for Phase 1 was incidence of dose-limiting toxicities (DLTs). Key secondary endpoints included incidence and time to onset and resolution of adverse events (AEs), rate of undetectable MRD remission in the bone marrow using flow cytometry, and duration of remission. KTE-C19 expansion and persistence were also assessed. Safety analyses included all patients who received KTE-C19, and patients with ≥ 2 months of follow-up were evaluated for efficacy.
Results: As of April 12, 2018, 35 patients have received KTE-C19 with a median follow-up of 11 months (range, 2 - 25 months). The median age was 40 years (range, 18 - 69 years), 51% of patients were male, 66% had ECOG 1, 13 patients (37%) had prior blinatumomab, and 60% had received ≥ 3 prior lines of treatment. The median bone marrow blast burden at screening was 70% (range, 5 - 100).
Six patients received the 2 × 106 cells/kg dose, 14 received 1 × 106 cells/kg, and 15 received 0.5 × 106 cells/kg. No DLTs were observed in the DLT period. The most common Grade ≥ 3 AEs were hypotension (40%), pyrexia (34%), decreased platelet counts (34%), and anemia (31%). Grade ≥ 3 CRS occurred in 9 patients (26%), with a median time to onset of 5 days (range, 1 - 15 days). There were 2 KTE-C19-related Grade 5 events: 1 cerebral infarction at the 0.5 × 106 cells/kg dose and 1 previously reported multiorgan failure secondary to cytokine release syndrome (CRS) at the 2 × 106 cells/kg dose. Grade ≥ 3 CRS resolved in all patients (not including 2 patients with a Grade 5 event), and the median time to resolution was 11 days (range, 7 - 42 days). Grade ≥ 3 treatment-emergent neurologic events occurred in 16 patients (46%), and the median time to onset was 7 days (range, 4 - 24 days). With the exception of 2 patients with unresolved neurologic events due to death, Grade ≥ 3 neurologic events resolved in all patients (14/14), with a median time to resolution of 17 days (range, 6 - 53 days).
Among the 32 patients evaluable for response, the overall rate of undetectable MRD was 78% (95% CI, 60% - 91%). CR or CRi was achieved by 23 patients (72%), and 1 patient (3%) had blast-free BM. KTE-C19 levels were examined in 23 patients as of July 31, 2017. Robust KTE-C19 expansion was observed across all dose levels assessed.
Conclusion: High rates of remission were achieved by adult patients with R/R ALL, with approximately three-quarters of patients achieving CR or CRi with undetectable MRD after a single dose of KTE-C19 in ZUMA-3. The safety profile was generally manageable, and most cases of high-grade CRS and neurologic events resolved. These results demonstrate that KTE-C19 offers clinical benefit for patients with otherwise limited treatment options.
Wierda:AbbVie, Inc: Research Funding; Genentech: Research Funding. Bishop:United Healthcare: Employment; Seattle Genetics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Speakers Bureau; Juneau Therapeutics: Speakers Bureau; Novartis Pharmaceuticals Corporation: Speakers Bureau. Logan:Adaptive Biotech: Consultancy; Napajen: Consultancy; Shire: Consultancy; Pfizer: Consultancy; Novartis: Consultancy, Research Funding; Incyte: Consultancy; Jazz Pharmaceuticals: Consultancy, Research Funding; Amgen: Consultancy; Astellas: Research Funding; Pharmacyclics: Research Funding; Kite: Research Funding. Schiller:Astellas Pharma: Membership on an entity's Board of Directors or advisory committees, Research Funding; bluebird bio: Research Funding. Holmes:Unum: Research Funding; Seattle Genetics: Research Funding, Speakers Bureau; Novartis: Research Funding; Genentech: Research Funding; Celgene: Research Funding; Rigel: Consultancy; Gilead: Consultancy, Research Funding, Speakers Bureau; Bayer: Consultancy. Abedi:Seattle Genetics: Speakers Bureau; Celgene: Speakers Bureau; Amgen: Research Funding; CIRM: Research Funding; BMS: Speakers Bureau; Takeda: Speakers Bureau; Gilead: Speakers Bureau; Celgene: Research Funding. Arellano:Cephalon: Research Funding. Pagel:Pharmacyclics, an AbbVie Company: Consultancy; Gilead: Consultancy. Mardiros:Kite, a Gilead Company: Employment; Kite, a Gilead Company: Equity Ownership; Mustang Bio: Patents & Royalties; Kite, a Gilead Company: Other: TRAVEL, ACCOMMODATIONS, EXPENSES. Shen:Zhejiang DTRM Biopharma LLC: Other: Clinical Operations Director. Vezan:Kite Pharma: Employment; Kite, Gilead, Abbv, MRK: Equity Ownership. Jain:Kite Pharma, Amgen: Equity Ownership; Kite Pharma: Employment; Kite Pharma: Patents & Royalties. |
---|---|
AbstractList | Abstract
Background: Although approximately half of adult patients with acute lymphoblastic leukemia (ALL) achieve long-term survival, those who relapse have poor long-term outcomes (El Fakih et al. Hematol Oncol Stem Cell Ther. 2017; Oriol et al. Haematologica. 2010). The initial report of Phase 1 of ZUMA-3, the Phase 1/2 trial of KTE-C19 for treatment of relapsed/refractory (R/R) ALL (NCT02614066), has thus far demonstrated promising efficacy among patients infused with KTE-C19, with a 71% complete remission (CR) rate (CR or CR with incomplete hematologic recovery [CRi]), 88% undetectable minimal residual disease (MRD), and manageable toxicity across all doses (Shah et al. ASH 2017. #888). Here, we present updated safety and efficacy data from Phase 1 of ZUMA-3.
Methods: Adult patients (≥ 18 y) with R/R ALL (Ph+ allowed), > 5% bone marrow blasts, and ECOG 0-1 received 2, 1, or 0.5 × 106 CAR T cells/kg after low-dose conditioning chemotherapy with fludarabine 25 mg/m2/day for 3 days and a single dose of cyclophosphamide 900 mg/m2 on the third day of conditioning. The primary endpoint for Phase 1 was incidence of dose-limiting toxicities (DLTs). Key secondary endpoints included incidence and time to onset and resolution of adverse events (AEs), rate of undetectable MRD remission in the bone marrow using flow cytometry, and duration of remission. KTE-C19 expansion and persistence were also assessed. Safety analyses included all patients who received KTE-C19, and patients with ≥ 2 months of follow-up were evaluated for efficacy.
Results: As of April 12, 2018, 35 patients have received KTE-C19 with a median follow-up of 11 months (range, 2 - 25 months). The median age was 40 years (range, 18 - 69 years), 51% of patients were male, 66% had ECOG 1, 13 patients (37%) had prior blinatumomab, and 60% had received ≥ 3 prior lines of treatment. The median bone marrow blast burden at screening was 70% (range, 5 - 100).
Six patients received the 2 × 106 cells/kg dose, 14 received 1 × 106 cells/kg, and 15 received 0.5 × 106 cells/kg. No DLTs were observed in the DLT period. The most common Grade ≥ 3 AEs were hypotension (40%), pyrexia (34%), decreased platelet counts (34%), and anemia (31%). Grade ≥ 3 CRS occurred in 9 patients (26%), with a median time to onset of 5 days (range, 1 - 15 days). There were 2 KTE-C19-related Grade 5 events: 1 cerebral infarction at the 0.5 × 106 cells/kg dose and 1 previously reported multiorgan failure secondary to cytokine release syndrome (CRS) at the 2 × 106 cells/kg dose. Grade ≥ 3 CRS resolved in all patients (not including 2 patients with a Grade 5 event), and the median time to resolution was 11 days (range, 7 - 42 days). Grade ≥ 3 treatment-emergent neurologic events occurred in 16 patients (46%), and the median time to onset was 7 days (range, 4 - 24 days). With the exception of 2 patients with unresolved neurologic events due to death, Grade ≥ 3 neurologic events resolved in all patients (14/14), with a median time to resolution of 17 days (range, 6 - 53 days).
Among the 32 patients evaluable for response, the overall rate of undetectable MRD was 78% (95% CI, 60% - 91%). CR or CRi was achieved by 23 patients (72%), and 1 patient (3%) had blast-free BM. KTE-C19 levels were examined in 23 patients as of July 31, 2017. Robust KTE-C19 expansion was observed across all dose levels assessed.
Conclusion: High rates of remission were achieved by adult patients with R/R ALL, with approximately three-quarters of patients achieving CR or CRi with undetectable MRD after a single dose of KTE-C19 in ZUMA-3. The safety profile was generally manageable, and most cases of high-grade CRS and neurologic events resolved. These results demonstrate that KTE-C19 offers clinical benefit for patients with otherwise limited treatment options.
Disclosures
Wierda: AbbVie, Inc: Research Funding; Genentech: Research Funding. Bishop:United Healthcare: Employment; Seattle Genetics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Speakers Bureau; Juneau Therapeutics: Speakers Bureau; Novartis Pharmaceuticals Corporation: Speakers Bureau. Logan:Adaptive Biotech: Consultancy; Napajen: Consultancy; Shire: Consultancy; Pfizer: Consultancy; Novartis: Consultancy, Research Funding; Incyte: Consultancy; Jazz Pharmaceuticals: Consultancy, Research Funding; Amgen: Consultancy; Astellas: Research Funding; Pharmacyclics: Research Funding; Kite: Research Funding. Schiller:Astellas Pharma: Membership on an entity's Board of Directors or advisory committees, Research Funding; bluebird bio: Research Funding. Holmes:Unum: Research Funding; Seattle Genetics: Research Funding, Speakers Bureau; Novartis: Research Funding; Genentech: Research Funding; Celgene: Research Funding; Rigel: Consultancy; Gilead: Consultancy, Research Funding, Speakers Bureau; Bayer: Consultancy. Abedi:Seattle Genetics: Speakers Bureau; Celgene: Speakers Bureau; Amgen: Research Funding; CIRM: Research Funding; BMS: Speakers Bureau; Takeda: Speakers Bureau; Gilead: Speakers Bureau; Celgene: Research Funding. Arellano:Cephalon: Research Funding. Pagel:Pharmacyclics, an AbbVie Company: Consultancy; Gilead: Consultancy. Mardiros:Kite, a Gilead Company: Employment; Kite, a Gilead Company: Equity Ownership; Mustang Bio: Patents & Royalties; Kite, a Gilead Company: Other: TRAVEL, ACCOMMODATIONS, EXPENSES. Shen:Zhejiang DTRM Biopharma LLC: Other: Clinical Operations Director. Vezan:Kite Pharma: Employment; Kite, Gilead, Abbv, MRK: Equity Ownership. Jain:Kite Pharma, Amgen: Equity Ownership; Kite Pharma: Employment; Kite Pharma: Patents & Royalties. Background: Although approximately half of adult patients with acute lymphoblastic leukemia (ALL) achieve long-term survival, those who relapse have poor long-term outcomes (El Fakih et al. Hematol Oncol Stem Cell Ther. 2017; Oriol et al. Haematologica. 2010). The initial report of Phase 1 of ZUMA-3, the Phase 1/2 trial of KTE-C19 for treatment of relapsed/refractory (R/R) ALL (NCT02614066), has thus far demonstrated promising efficacy among patients infused with KTE-C19, with a 71% complete remission (CR) rate (CR or CR with incomplete hematologic recovery [CRi]), 88% undetectable minimal residual disease (MRD), and manageable toxicity across all doses (Shah et al. ASH 2017. #888). Here, we present updated safety and efficacy data from Phase 1 of ZUMA-3. Methods: Adult patients (≥ 18 y) with R/R ALL (Ph+ allowed), > 5% bone marrow blasts, and ECOG 0-1 received 2, 1, or 0.5 × 106 CAR T cells/kg after low-dose conditioning chemotherapy with fludarabine 25 mg/m2/day for 3 days and a single dose of cyclophosphamide 900 mg/m2 on the third day of conditioning. The primary endpoint for Phase 1 was incidence of dose-limiting toxicities (DLTs). Key secondary endpoints included incidence and time to onset and resolution of adverse events (AEs), rate of undetectable MRD remission in the bone marrow using flow cytometry, and duration of remission. KTE-C19 expansion and persistence were also assessed. Safety analyses included all patients who received KTE-C19, and patients with ≥ 2 months of follow-up were evaluated for efficacy. Results: As of April 12, 2018, 35 patients have received KTE-C19 with a median follow-up of 11 months (range, 2 - 25 months). The median age was 40 years (range, 18 - 69 years), 51% of patients were male, 66% had ECOG 1, 13 patients (37%) had prior blinatumomab, and 60% had received ≥ 3 prior lines of treatment. The median bone marrow blast burden at screening was 70% (range, 5 - 100). Six patients received the 2 × 106 cells/kg dose, 14 received 1 × 106 cells/kg, and 15 received 0.5 × 106 cells/kg. No DLTs were observed in the DLT period. The most common Grade ≥ 3 AEs were hypotension (40%), pyrexia (34%), decreased platelet counts (34%), and anemia (31%). Grade ≥ 3 CRS occurred in 9 patients (26%), with a median time to onset of 5 days (range, 1 - 15 days). There were 2 KTE-C19-related Grade 5 events: 1 cerebral infarction at the 0.5 × 106 cells/kg dose and 1 previously reported multiorgan failure secondary to cytokine release syndrome (CRS) at the 2 × 106 cells/kg dose. Grade ≥ 3 CRS resolved in all patients (not including 2 patients with a Grade 5 event), and the median time to resolution was 11 days (range, 7 - 42 days). Grade ≥ 3 treatment-emergent neurologic events occurred in 16 patients (46%), and the median time to onset was 7 days (range, 4 - 24 days). With the exception of 2 patients with unresolved neurologic events due to death, Grade ≥ 3 neurologic events resolved in all patients (14/14), with a median time to resolution of 17 days (range, 6 - 53 days). Among the 32 patients evaluable for response, the overall rate of undetectable MRD was 78% (95% CI, 60% - 91%). CR or CRi was achieved by 23 patients (72%), and 1 patient (3%) had blast-free BM. KTE-C19 levels were examined in 23 patients as of July 31, 2017. Robust KTE-C19 expansion was observed across all dose levels assessed. Conclusion: High rates of remission were achieved by adult patients with R/R ALL, with approximately three-quarters of patients achieving CR or CRi with undetectable MRD after a single dose of KTE-C19 in ZUMA-3. The safety profile was generally manageable, and most cases of high-grade CRS and neurologic events resolved. These results demonstrate that KTE-C19 offers clinical benefit for patients with otherwise limited treatment options. Wierda:AbbVie, Inc: Research Funding; Genentech: Research Funding. Bishop:United Healthcare: Employment; Seattle Genetics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Speakers Bureau; Juneau Therapeutics: Speakers Bureau; Novartis Pharmaceuticals Corporation: Speakers Bureau. Logan:Adaptive Biotech: Consultancy; Napajen: Consultancy; Shire: Consultancy; Pfizer: Consultancy; Novartis: Consultancy, Research Funding; Incyte: Consultancy; Jazz Pharmaceuticals: Consultancy, Research Funding; Amgen: Consultancy; Astellas: Research Funding; Pharmacyclics: Research Funding; Kite: Research Funding. Schiller:Astellas Pharma: Membership on an entity's Board of Directors or advisory committees, Research Funding; bluebird bio: Research Funding. Holmes:Unum: Research Funding; Seattle Genetics: Research Funding, Speakers Bureau; Novartis: Research Funding; Genentech: Research Funding; Celgene: Research Funding; Rigel: Consultancy; Gilead: Consultancy, Research Funding, Speakers Bureau; Bayer: Consultancy. Abedi:Seattle Genetics: Speakers Bureau; Celgene: Speakers Bureau; Amgen: Research Funding; CIRM: Research Funding; BMS: Speakers Bureau; Takeda: Speakers Bureau; Gilead: Speakers Bureau; Celgene: Research Funding. Arellano:Cephalon: Research Funding. Pagel:Pharmacyclics, an AbbVie Company: Consultancy; Gilead: Consultancy. Mardiros:Kite, a Gilead Company: Employment; Kite, a Gilead Company: Equity Ownership; Mustang Bio: Patents & Royalties; Kite, a Gilead Company: Other: TRAVEL, ACCOMMODATIONS, EXPENSES. Shen:Zhejiang DTRM Biopharma LLC: Other: Clinical Operations Director. Vezan:Kite Pharma: Employment; Kite, Gilead, Abbv, MRK: Equity Ownership. Jain:Kite Pharma, Amgen: Equity Ownership; Kite Pharma: Employment; Kite Pharma: Patents & Royalties. |
Author | Shah, Bijal D. Baer, Maria R. O'Dwyer, Kristen M. Shen, Tong Donnellan, William B. Ghobadi, Armin Arellano, Martha L. Mardiros, Armen Jain, Rajul K. Wierda, William G. Schiller, Gary J. Pagel, John M. Malone, Adriana K. Oluwole, Olalekan O. Logan, Aaron C. Holmes, Houston Castro, Januario E. Vezan, Remus Bishop, Michael R. Abedi, Mehrdad |
Author_xml | – sequence: 1 givenname: William G. surname: Wierda fullname: Wierda, William G. organization: Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX – sequence: 2 givenname: Michael R. surname: Bishop fullname: Bishop, Michael R. organization: Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL – sequence: 3 givenname: Olalekan O. surname: Oluwole fullname: Oluwole, Olalekan O. organization: Vanderbilt-Ingram Cancer Center, Nashville, TN – sequence: 4 givenname: Aaron C. surname: Logan fullname: Logan, Aaron C. organization: Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA – sequence: 5 givenname: Maria R. surname: Baer fullname: Baer, Maria R. organization: University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD – sequence: 6 givenname: William B. surname: Donnellan fullname: Donnellan, William B. organization: Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN – sequence: 7 givenname: Kristen M. surname: O'Dwyer fullname: O'Dwyer, Kristen M. organization: Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY – sequence: 8 givenname: Januario E. surname: Castro fullname: Castro, Januario E. organization: Mayo Clinic, Scottsdale, AZ – sequence: 9 givenname: Gary J. surname: Schiller fullname: Schiller, Gary J. organization: David Geffen School of Medicine at UCLA, Los Angeles, CA – sequence: 10 givenname: Houston surname: Holmes fullname: Holmes, Houston organization: Texas Oncology, P.A./Baylor-Sammons Cancer Center, Dallas, TX – sequence: 11 givenname: Mehrdad surname: Abedi fullname: Abedi, Mehrdad organization: Comprehensive Cancer Center, Division of Hematology/Oncology, University of California Davis Medical Center, Sacramento, CA – sequence: 12 givenname: Armin surname: Ghobadi fullname: Ghobadi, Armin organization: Washington University School of Medicine and Siteman Cancer Center, St. Louis, MO – sequence: 13 givenname: Martha L. surname: Arellano fullname: Arellano, Martha L. organization: Winship Cancer Institute, Emory University, Atlanta, GA – sequence: 14 givenname: Adriana K. surname: Malone fullname: Malone, Adriana K. organization: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY – sequence: 15 givenname: John M. surname: Pagel fullname: Pagel, John M. organization: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA – sequence: 16 givenname: Armen surname: Mardiros fullname: Mardiros, Armen organization: Kite, a Gilead Company, Santa Monica, CA – sequence: 17 givenname: Tong surname: Shen fullname: Shen, Tong organization: Kite, a Gilead Company, Santa Monica, CA – sequence: 18 givenname: Remus surname: Vezan fullname: Vezan, Remus organization: Kite, a Gilead Company, Santa Monica, CA – sequence: 19 givenname: Rajul K. surname: Jain fullname: Jain, Rajul K. organization: Kite, a Gilead Company, Santa Monica, CA – sequence: 20 givenname: Bijal D. surname: Shah fullname: Shah, Bijal D. organization: H. Lee Moffitt Cancer Center, Tampa, FL |
BookMark | eNp9kEtOHDEQQK2ISBlIbpCFD4DB1d1u2iwijRoSECMFoWGTjeVPddqkf7I9ieZKOSWGYc3KUsnvqeodk6NpnpCQr8DPAJri3Azz7FjBoWFSMgAQJXwgKxBFwzgv-BFZcc5rVskL-ESOY3ziHKqyECvy_3FxOqGj972OSIE-YNwNKdK5o792o2blJb1LyFqQp1RPdD0lz9orkLTt_YjB29fRb5wyaXFJc6Bb2uIw0G2PQS_7U-oz5rKU3uvkccryfz71-f-gl4ju_AG7oG0m93RtdwnpZj8u_WwGHVP2b3D3B0evP5OPnR4ifnl7T8jj9-tte8M2P3_ctusNsyAAGEqjZckNt9ZK5I21xgmDrkKnoTa1lABVbbRwHcq6EvZCVNqKrqu16WzTlCekOnhtmGMM2Kkl-FGHvQKuXnqr197qpbeSUh16Z-zbAcO821-PQUWbr7XofECblJv9-4JnVh6NEQ |
CitedBy_id | crossref_primary_10_1186_s12885_021_09102_x crossref_primary_10_1097_PPO_0000000000000375 crossref_primary_10_1038_s41375_019_0615_5 crossref_primary_10_1016_j_soncn_2019_150951 crossref_primary_10_1182_hematology_2020000133 crossref_primary_10_1200_JCO_20_01616 crossref_primary_10_1016_j_clml_2020_06_011 |
ContentType | Journal Article |
Copyright | 2018 American Society of Hematology |
Copyright_xml | – notice: 2018 American Society of Hematology |
DBID | 6I. AAFTH AAYXX CITATION |
DOI | 10.1182/blood-2018-99-111531 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Biology Anatomy & Physiology |
EISSN | 1528-0020 |
EndPage | 897 |
ExternalDocumentID | 10_1182_blood_2018_99_111531 S0006497119369460 |
GroupedDBID | --- -~X .55 1CY 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6I. 6J9 AAEDW AAFTH AAXUO ABOCM ABVKL ACGFO ADBBV AENEX AFOSN AHPSJ ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW CS3 DIK DU5 E3Z EBS EJD EX3 F5P FDB FRP GS5 GX1 IH2 K-O KQ8 L7B LSO MJL N9A OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV ZA5 0R~ 0SF AALRI AAYXX ADVLN AFETI AITUG AKRWK CITATION H13 |
ID | FETCH-LOGICAL-c1511-e9ba930b0ccc9e08ccbd5bed4eda16b6991146ba5dfe9645c754ac5ff6abfc883 |
IEDL.DBID | ABVKL |
ISSN | 0006-4971 |
IngestDate | Thu Sep 12 19:27:47 EDT 2024 Fri Feb 23 02:41:27 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement 1 |
Language | English |
License | This article is made available under the Elsevier license. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c1511-e9ba930b0ccc9e08ccbd5bed4eda16b6991146ba5dfe9645c754ac5ff6abfc883 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0006497119369460 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1182_blood_2018_99_111531 elsevier_sciencedirect_doi_10_1182_blood_2018_99_111531 |
PublicationCentury | 2000 |
PublicationDate | 2018-11-29 |
PublicationDateYYYYMMDD | 2018-11-29 |
PublicationDate_xml | – month: 11 year: 2018 text: 2018-11-29 day: 29 |
PublicationDecade | 2010 |
PublicationTitle | Blood |
PublicationYear | 2018 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
SSID | ssj0014325 |
Score | 2.3294046 |
Snippet | Background: Although approximately half of adult patients with acute lymphoblastic leukemia (ALL) achieve long-term survival, those who relapse have poor... Abstract Background: Although approximately half of adult patients with acute lymphoblastic leukemia (ALL) achieve long-term survival, those who relapse have... |
SourceID | crossref elsevier |
SourceType | Aggregation Database Publisher |
StartPage | 897 |
Title | Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia |
URI | https://dx.doi.org/10.1182/blood-2018-99-111531 |
Volume | 132 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5VqXhcEKQgyqOaA-LUVfxax8vNNVSFBIRQgiou1j7GqkXqRIl9yF_iVzK7dhBIiAM3a6WR1jvjmW88s98w9iqaWq0CobgSkeCJEsgzi5mrFCrH5h1nxrN9fkqvlsmHa3F9xIrDXRjXVjn4_t6ne289rEyG05xs6trd8aVwKqdh6GbSJSnl7ceRKzON2HF-8XU2_1VMSOKoH2RAybMTGG7QEbKe9N3hFARpd5LTdy_i8O8R6reoc_mQPRjgIuT9jh6xI2zG7CRvKFW-3cNr8A2c_s_4mN25ODzdKw5j3Mbs7sehen7Cfiw3Lr-3JEWxC0L4grtu1e5gXcG37lbx-A3MWuRFKM9BNZA3bc2Lt6GE4qb2lR2_RCZHkq4dZr2FBRS4WsGiJyc4h5rEHKUHfO4JW3fg_vSC67nb7NBxzlZbP-JnD7npWoT5nuxprQnE0yvCHLvvtHX1mC0v3y2KKz7MauCGMEPIUWol40AHxhiJQWaMtkKjTdCqMNUpwVDyyVoJW6FME2GmIlFGVFWqdGWyLH7CRs26wacMIoIwWiZWhqgSi0ZZpTIZYCArW6VanzJ-0E-56Sk5Sp_KZFHp9Vk6fZZSlr0-T9n0oMTyD9MqKWr8U_LZf0s-Z_e9UdHJRPIFG7XbDl8Semn12WCdZ4Tf389-AiKY7gE |
link.rule.ids | 315,786,790,27600,27955,27956,45696 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5VraC9oJKCaMtjDohTV_FrHS8316UKxK0QSlDFxdqXhdXUiRL7kL_Er2R2bSOQEAdu1kojrXfGM994Zr8h5G0w0VJ4TFDBAkYjwQxNtElspVBYNu8wUY7t8zaeLqJPd-xuj2TDXRjbVtn7_s6nO2_dr4z70xyvq8re8cVwyie-b2fSRTHm7QeIBjia-UF6-XWW_yomRGHQDTLA5NkK9DfoEFmPu-5wDIK4O07xu2eh__cI9VvUuT4mT3q4CGm3o6dkz9QjcpLWmCo_7OAduAZO92d8RB5dDk-H2TDGbUQe3_TV8xPyY7G2-b1GKYxd4MMXs22XzRZWJXxrHwQN38OsMTTz-QWIGtK6qWh25XPIvleusuOW0ORQ0rbDrDYwh8wslzDvyAkuoEIxS-kBnzvC1i3YP71ge-7WW2M5Z8uNG_Gzg1S1jYF8h_a0kgji8RUhN-09bl08I4vrD_NsSvtZDVQhZvCp4VLw0JOeUoobL1FKaiaNjowWfixjhKHok6VgujQ8jpiasEgoVpaxkKVKkvA52a9XtXlBIEAII3mkuW9EpI0SWoiEe8bjpS5jKU8JHfRTrDtKjsKlMklQOH0WVp8F50Wnz1MyGZRY_GFaBUaNf0qe_bfkG3I4nd_kRf7xdnZOjpyB4SkF_CXZbzateYVIppGve0v9CfZw8AE |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Updated+Phase+1+Results+of+Zuma-3%3A+Kte-C19%2C+an+Anti-CD19+Chimeric+Antigen+Receptor+T+Cell+Therapy%2C+in+Adult+Patients+with+Relapsed%2FRefractory+Acute+Lymphoblastic+Leukemia&rft.jtitle=Blood&rft.au=Wierda%2C+William+G.&rft.au=Bishop%2C+Michael+R.&rft.au=Oluwole%2C+Olalekan+O.&rft.au=Logan%2C+Aaron+C.&rft.date=2018-11-29&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=132&rft.issue=Supplement+1&rft.spage=897&rft.epage=897&rft_id=info:doi/10.1182%2Fblood-2018-99-111531&rft.externalDBID=n%2Fa&rft.externalDocID=10_1182_blood_2018_99_111531 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon |